These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10969772)

  • 1. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
    Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
    Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
    Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
    J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
    Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M
    J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
    Le Gall F; Reusch U; Little M; Kipriyanov SM
    Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.